Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 12 of 41.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2010-020825-42 Sponsor Protocol Number: RTOG0815 Start Date*: 2010-11-08
    Sponsor Name:Radiation Therapy Oncology Group
    Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
    Medical condition: intermediate risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002667-53 Sponsor Protocol Number: 213409 Start Date*: 2021-08-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit...
    Medical condition: advanced ovarian, breast, or prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000476-26 Sponsor Protocol Number: N14DAR Start Date*: 2020-07-13
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA)
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036912 Prostate cancer stage 0 PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036917 Prostate cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036919 Prostate cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000305-21 Sponsor Protocol Number: ASCB-Onco-2336-2017 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospectic, phase II, randomized, ...
    Medical condition: prostate cancer with hormone sensitive metastatic bone disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036927 Prostate neoplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002030-36 Sponsor Protocol Number: CA2097DX Start Date*: 2019-11-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer
    Medical condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) CZ (Completed) IT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003190-96 Sponsor Protocol Number: SHR-3680-III-HSPC Start Date*: 2020-02-10
    Sponsor Name:Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Full Title: One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensiti...
    Medical condition: Metastatic hormone-sensitive prostate cancer with high tumor load
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019158-41 Sponsor Protocol Number: IPS-TRI-2010-03 Start Date*: 2011-07-21
    Sponsor Name:IPSEN PHARMA, S.A.
    Full Title: ENSAYO CLÍNICO DE PRUEBA DE CONCEPTO, MULTICÉNTRICO, PROSPECTIVO, ALEATORIZADO, ABIERTO Y PARALELO, PARA VALORAR LA EFICACIA DE LA BRAQUITERAPIA CON O SIN TRATAMIENTO HORMONAL CON TRIPTORELINA 22,5...
    Medical condition: Cáncer de Próstata
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003386-22 Sponsor Protocol Number: PRX302-2-07 Start Date*: 2015-01-19
    Sponsor Name:Sophiris Bio Corp
    Full Title: A Single Centre, Open Label, Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Signific...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002846-61 Sponsor Protocol Number: ACT15319 Start Date*: 2018-04-10
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination with REGN2810, or Isatuximab alone, in Patients with Advan...
    Medical condition: - Prostate cancer - Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002702-21 Sponsor Protocol Number: inecalcitol-CT2 Start Date*: 2007-09-06
    Sponsor Name:Hybrigenics SA
    Full Title: Dose finding Phase 2a Study of Inecalcitol in Combination with Standard Docetaxel Prednisone Regimen in Hormone-Refractory Prostate Cancer
    Medical condition: hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004489-32 Sponsor Protocol Number: CV-9104-007 Start Date*: 2014-03-05
    Sponsor Name:CureVac AG
    Full Title: An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer
    Medical condition: prostate carcinoma (intermediate and high risk)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001302-15 Sponsor Protocol Number: BIO-CT-001 Start Date*: 2019-09-13
    Sponsor Name:BIOKOSMOS S.A.
    Full Title: Phase III study of Positron/Computerized Tomography (PETCT) with F-18-PSMA-1007 versus F-18-Fluorocholine to compare the detection rate of prostate cancer lesions in patients with biochemical recur...
    Medical condition: Prostate cancer recurrent
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017668-18 Sponsor Protocol Number: C18002 Start Date*: 2010-04-29
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 1/2, Open-Label Study in Men with Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomi...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001961-33 Sponsor Protocol Number: CFG920X2101 Start Date*: 2013-01-29
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer
    Medical condition: Metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Temporarily Halted) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018370-21 Sponsor Protocol Number: C-II-007 Start Date*: 2010-05-27
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research EWIV
    Full Title: Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy CESAR Study in Prostrate Cancer wi...
    Medical condition: castration resistant prostate cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007969-23 Sponsor Protocol Number: CC-5013-PC-002 Start Date*: 2010-04-09
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER
    Medical condition: Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) HU (Completed) CZ (Prematurely Ended) DE (Completed) GB (Completed) AT (Completed) NL (Completed) IT (Completed) ES (Completed) DK (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002940-26 Sponsor Protocol Number: 212082PCR3011 Start Date*: 2013-05-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me...
    Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004377-13 Sponsor Protocol Number: CA209-9HX Start Date*: 2018-11-21
    Sponsor Name:SOGUG (Spanish Genitourinary Oncologic Group)
    Full Title: A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer.
    Medical condition: metastatic hormone-sensitive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003869-28 Sponsor Protocol Number: 9785-CL-0335 Start Date*: 2016-08-04
    Sponsor Name:Astellas Pharma Global Development, Inc (APGD)
    Full Title: ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients ...
    Medical condition: Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing) BE (Completed) ES (Restarted) DK (Completed) FI (Completed) SE (Completed) DE (Completed) SK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000625-37 Sponsor Protocol Number: BED-004 Start Date*: 2015-08-28
    Sponsor Name:Blue Earth Diagnostics Limited
    Full Title: A phase 3, open-label study to assess the clinical utility of fluciclovine (18F) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment
    Medical condition: Prostate cancer with biochemical recurrence after radical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 05:00:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA